Metformin

Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.

Diabetes medications are frequently unavailable and unaffordable, particularly in lower-income countries, shows an analysis of the PURE study.

The authors of a systematic review find insufficient evidence to support the use of metformin to improve pregnancy outcomes among obese women.

Jay Shubrook, Chair of the American Diabetes Association’s Primary Care Advisory Group, outlines what's new in 2018's ADA Standards of Care update. 

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.